SNSE vs. XGN, CTSO, BLRX, VTVT, HILS, ELDN, EYEN, HOOK, SLS, and PRPH
Should you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Exagen (XGN), Cytosorbents (CTSO), BioLineRx (BLRX), vTv Therapeutics (VTVT), Hillstream BioPharma (HILS), Eledon Pharmaceuticals (ELDN), Eyenovia (EYEN), Hookipa Pharma (HOOK), SELLAS Life Sciences Group (SLS), and ProPhase Labs (PRPH). These companies are all part of the "medical" sector.
Sensei Biotherapeutics (NASDAQ:SNSE) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership, community ranking and dividends.
Sensei Biotherapeutics currently has a consensus target price of $4.33, indicating a potential upside of 540.84%. Exagen has a consensus target price of $7.00, indicating a potential upside of 248.26%. Given Sensei Biotherapeutics' higher possible upside, equities analysts clearly believe Sensei Biotherapeutics is more favorable than Exagen.
Sensei Biotherapeutics received 6 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 78.79% of users gave Sensei Biotherapeutics an outperform vote while only 54.05% of users gave Exagen an outperform vote.
Sensei Biotherapeutics has a net margin of 0.00% compared to Exagen's net margin of -34.74%. Sensei Biotherapeutics' return on equity of -46.67% beat Exagen's return on equity.
Exagen has higher revenue and earnings than Sensei Biotherapeutics. Exagen is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 25.5% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 26.1% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Exagen had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 3 mentions for Exagen and 2 mentions for Sensei Biotherapeutics. Exagen's average media sentiment score of 0.96 beat Sensei Biotherapeutics' score of 0.93 indicating that Exagen is being referred to more favorably in the news media.
Sensei Biotherapeutics has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.
Summary
Exagen beats Sensei Biotherapeutics on 9 of the 16 factors compared between the two stocks.
Get Sensei Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensei Biotherapeutics Competitors List
Related Companies and Tools
